[1]赵秋朴,李秋明,胡芷柔.黄斑前膜剥除术联合地塞米松缓释剂（Ozurdex）玻璃体内注射治疗4期黄斑前膜的疗效分析[J].眼科新进展,2022,42(7):538-541.[doi:10.13389/j.cnki.rao.2022.0110]
　ZHAO Qiupu,LI Qiuming,HU Zhirou.Efficacy of macular epiretinal membrane dissection combined with intravitreal injection of Ozurdex for stage 4 epiretinal membrane[J].Recent Advances in Ophthalmology,2022,42(7):538-541.[doi:10.13389/j.cnki.rao.2022.0110]
点击复制

黄斑前膜剥除术联合地塞米松缓释剂（Ozurdex）玻璃体内注射治疗4期黄斑前膜的疗效分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年7期
页码:
538-541
栏目:
应用研究
出版日期:
2022-07-05

文章信息/Info

Title:
Efficacy of macular epiretinal membrane dissection combined with intravitreal injection of Ozurdex for stage 4 epiretinal membrane
作者:
赵秋朴; 李秋明; 胡芷柔
450052　河南省郑州市，郑州大学第一附属医院眼科
Author(s):
ZHAO Qiupu;  LI Qiuming;  HU Zhirou
Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
关键词:
黄斑前膜; 地塞米松缓释剂; 视力; 黄斑水肿; 视网膜结构
Keywords:
macular epiretinal membrane;  Ozurdex;  visual acuity;  macular edema;  retinal structure
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2022.0110
文献标志码:
A
摘要:
目的　评价黄斑前膜（ERM）剥除术联合地塞米松缓释剂（Ozurdex）玻璃体内注射治疗4期ERM患者的效果和安全性。方法　回顾性研究。纳入2019年3月至2021年6月在郑州大学第一附属医院眼科诊断为4期ERM并于ERM剥除术中联合应用Ozurdex玻璃体内注射的患者26例（26眼），分析手术前和术后1个月、3个月、6个月的最佳矫正视力（BCVA）、黄斑中心厚度（CMT）、眼压及术后黄斑区视网膜结构变化和术后并发症情况。结果　患者手术前和术后1个月、3个月、6个月的BCVA（logMAR）分别为0.70（0.52，1.08）、0.52（0.37，1.00）、0.46（0.28，0.70）和0.40（0.28，0.70），术后各时间点的BCVA较术前均有好转（均为P<0.05）；手术前和术后1个月、3个月、6个月的CMT分别为651.50 μm（538.30 μm，790.80 μm）、387.00 μm（342.80 μm，423.30 μm）、363.50 μm（321.80 μm，419.30 μm）和339.50 μm（305.80 μm，374.80 μm），术后各时间点的CMT较术前均有明显改善（均为P<0.001）；手术前后的眼压差异无统计学意义（P=0.094），其中6例患者眼压升高，且≥25 mmHg（1 kPa=7.5 mmHg）；术后6个月，ERM由4期改善为1期者2眼（7.7%），改善至3期者9眼（34.6%），仍为4期者有15眼（57.7%），但其黄斑区视网膜结构紊乱程度较术前减轻；术前BCVA与术后6个月的BCVA呈正相关（r=0.713，P<0.001）；7例(26.9%)患者在随访期内出现黄斑水肿，未发生眼部或全身严重并发症。结论　ERM剥除术联合Ozurdex玻璃体内注射可改善4期ERM患者视力，并促进黄斑区视网膜解剖结构的恢复。
Abstract:
Objective　To evaluate the efficacy and safety of macular epiretinal membrane (ERM) dissection combined with intravitreal injection of Ozurdex for stage 4 ERM. Methods　Twenty-six patients (twenty-six eyes) who were diagnosed with stage 4 ERM and received ERM dissection combined with intravitreal injection of Ozurdex in the First Affiliated Hospital of Zhengzhou University from March 2019 to June 2021 were included in this retrospective study. The best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), macular retinal structure, and complications were analyzed preoperatively, 1 month, 3 months, and 6 months postoperatively. Results　The BCVA (logMAR) preoperatively, 1 month, 3 months, and 6 months postoperatively were 0.70 (0.52, 1.08), 0.52 (0.37, 1.00), 0.46 (0.28, 0.70), and 0.40 (0.28, 0.70), respectively. The postoperative BCVA was better than before operation (all P<0.05). The CMT preoperatively, 1 month, 3 months, and 6 months postoperatively were 651.50 μm (538.30 μm, 790.80 μm), 387.00 μm (342.80 μm, 423.30 μm), 363.50 μm (321.80 μm, 419.30 μm), and 339.50 μm (305.80 μm, 374.80 μm), respectively. The CMT improved significantly after operation (P<0.001). There was no significant difference in IOP before and after operation (P=0.094). Six patients had increased IOP, ≥ 25 mmHg (1 kPa=7.5 mmHg). Six months after operation, 2 eyes (7.7%) improved to stage 1, 9 eyes (34.6%) improved to stage 3, and 15 eyes (57.7%) were still in stage 4. However, the macular structural disorder in the 15 eyes with stage 4 ERM was alleviated than before operation. There was a positive correlation between preoperative BCVA and BCVA at 6 months after operation (r=0.713, P<0.001). Macular edema occurred in 7 eyes (26.9%) during the follow-up period. No serious ocular or systemic complications occurred. Conclusion　ERM dissection combined with intravitreal injection of Ozurdex can improve the visual acuity and the macular retinal structure of patients with stage 4 ERM.

参考文献/References:

［1］　GOVETTO A,LALANE R A 3rd,SARRAF D,FIGUEROA M S,HUBSCHMAN J P.Insights into epiretinal membranes:presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme［J］.Am J Ophthalmol,2017,175:99-113.
［2］　CHUA P Y,SANDINHA M T,STEEL D H.Idiopathic epireticne:progression and timing of surgery［J］.Eye,2022,36(3):495-503.
［3］　胡旭萌,李晓丽,李苗,黄子旭,张贝贝,魏圆梦,等.异位中心凹内层黄斑前膜分期方案对患者术后视力预后的评估［J］.眼科新进展,2021,41(11):1057-1061.
HU X M,LI X L,LI M,HUANG Z X,ZHANG B B,WEI Y M,et al.Effect of ectopic inner foveal layer staging scheme on the prognosis of patients’ postoperative vision outcomes［J］.Rec Adv Ophthalmol,2021,41(11):1057-1061.
［4］　CHATZIRALLI I,DIMITRIOU E,THEODOSSIADIS G,CHATZIRALLIS A,KAZANTZIS D,THEODOSSIADIS P.Treatment of macular edema after pars plana vitrectomy for idiopathic epiretinal membrane using intravitreal dexamethasone implant:long-term outcomes［J］.Ophthalmologica,2019,242(1):16-21.
［5］　王丽英,李洁,温晓英,张月玲.内界膜剥除联合玻璃体内注射曲安奈德治疗继发性黄斑前膜的疗效观察［J］.眼科新进展,2017,37(8):763-765.
WANG L Y,LI J,WEN X Y,ZHANG Y L.Efficacy of retinal inner limiting membrane peeling and intravitreal injection of triamcinolone acetonide for secondary epiretinal membrane［J］.Rec Adv Ophthalmol,2017,37(8):763-765.
［6］　CHIN H S,PARK T S,MOON Y S,OH J H.Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes［J］.Retina,2005,25(5):556-560.
［7］　HATTENBACH L O,SPRINGER-WANNER C,HOERAUF H,CALLIZO J,JUNGMANN S,BRAUNS T,et al.Intravitreal sustained-release steroid implants for the treatment of macular edema following surgical removal of epiretinal membranes［J］.Ophthalmologica,2017,237(4):232-237.
［8］　CHANG Y C,LIU P K,KAO T E,WU H J,CHENG K C,CHEN K J,et al.Dexamethasone intravitreal implant (Ozurdex) for long-term macular edema after epiretinal membrane peeling surgery［J］.J Ophthalmol,2018,2018:5832186.
［9］　HARTMANN K I,SCHUSTER A K,BARTSCH D U,KIM J S,CHHABLANI J,FREEMAN W R.Restoration of retinal layers after epiretinal membrane peeling［J］.Retina,2014,34(4):647-654.
［10］　AHN J H,PARK H J,LEE J E,OUM B S.Effect of intravitreal triamcinolone injection during vitrectomy for idiopathic epiretinal membrane［J］.Retina,2012,32(5):892-896.
［11］　BRINGMANN A,UNTERLAUFT J D,BARTH T,WIEDEMANN R,REHAK M,WIEDEMANN P.Foveal configurations with disappearance of the foveal pit in eyes with macular pucker:presumed role of müller cells in the formation of foveal herniation［J］.Exp Eye Res,2021,207:108604.
［12］　FUNG A T,GALVIN J,TRAN T.Epiretinal membrane:a review［J］.Clin Exp Ophthalmol,2021,49(3):289-308.
［13］　FRISINA R,PINACKATT S J,SARTORE M,MONFARDINI A,BALDI A,CESANA B M,et al.Cystoid macular edema after pars plana vitrectomy for idiopathic epiretinal membrane［J］.Graefes Arch Clin Exp Ophthalmol,2015,253(1):47-56.
［14］　REICHENBACH A,WURM A,PANNICKE T,IANDIEV I,WIEDEMANN P,BRINGMANN A.Müller cells as players in retinal degeneration and edema［J］.Graefes Arch Clin Exp Ophthalmol,2007,245(5):627-636.
［15］　JINAGAL J,GUPTA P C,PILANIA R K,RAM J.Systemic toxicity of topical corticosteroids［J］.Indian J Ophthalmol,2019,67(4):559-561.
［16］　BEER P M,BAKRI S J,SINGH R J,LIU W,PETERS G B 3rd,MILLER M.Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection［J］.Ophthalmology,2003,110(4):681-686.
［17］　FREISSINGER S,VOUNOTRYPIDIS E,WOLF A,KORTUEM K U,SHAJARI M,SAKKIAS F,et al.Evaluation of functional outcomes and oct-biomarkers after intravitreal dexamethasone implant for postoperative cystoid macular edema in vitrectomized eyes［J］.J Ophthalmol,2020,2020:3946531.
［18］　CHANG-LIN J E,BURKE J A,PENG Q,LIN T,ORILLA W C,GHOSN C R,et al.Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes［J］.Invest Ophthalmol Vis Sci,2011,52(7):4605-4609.
［19］　HOSTOVSKY A,MUNI R H,ENG K T,MULHALL D,LEUNG C,KERTES P J.Intraoperative dexamethasone intravitreal implant (Ozurdex) in vitrectomy surgery for epiretinal membrane［J］.Curr Eye Res,2020,45(6):737-741.
［20］　BANKER T P,REILLY G S,JALAJ S,WEICHEL E D.Epiretinal membrane and cystoid macular edema after retinal detachment repair with small-gauge pars plana vitrectomy［J］.Eur J Ophthalmol,2015,25(6):565-570.
［21］　MCCARTNEY M,MCCLUSKEY P,ZAGORA S.Intravitreal dexamethasone implants for non-infectious uveitis［J］.Clin Exp Ophthalmol,2019,47(9):1156-1163.

相似文献/References:

[1]王震 荣翱 莫利娟.23G 、25G 联合经结膜免缝合微创玻璃体切割术治疗黄斑前膜[J].眼科新进展,2012,32(3):000.
[2]刘鹏飞,廖奇志,刘淑伟,等. 23G玻璃体切割联合双重多次染色黄斑前膜、内界膜治疗黄斑裂孔性视网膜脱离[J].眼科新进展,2015,35(9):878.[doi:10.13389/j.cnki.rao.2015.0240]
　LIU Peng-Fei,LIAO Qi-Zhi,LIU Shu-Wei,et al. 23 gauge vitrectomy combined with double and multiple staining macular eptiretinal membrane and internal limiting membrane for macular hole retinal detachment[J].Recent Advances in Ophthalmology,2015,35(7):878.[doi:10.13389/j.cnki.rao.2015.0240]
[3]宋敬瑶,齐心竹,范斌.黄斑前膜的诊断治疗进展[J].眼科新进展,2016,36(11):1085.[doi:10.13389/j.cnki.rao.2016.0290]
　SONG Jing Yao,QI Xin-Zhu,FAN Bin.Recent advances in diagnosis and treatment of macular epiretinal membrane[J].Recent Advances in Ophthalmology,2016,36(7):1085.[doi:10.13389/j.cnki.rao.2016.0290]
[4]路迎龙,杜倩,李筱荣,等.葡萄膜炎继发黄斑囊样水肿的临床研究[J].眼科新进展,2017,37(2):147.[doi:10.13389/j.cnki.rao.2017.0039]
　LU Ying-Long,DU Qian,LI Xiao-Rong,et al.Efficacy of uveitis secondary to cystoid macular edema[J].Recent Advances in Ophthalmology,2017,37(7):147.[doi:10.13389/j.cnki.rao.2017.0039]
[5]宁玲.特发性黄斑前膜手术前后光学相干断层扫描形态变化与视力的关系[J].眼科新进展,2017,37(11):1068.[doi:10.13389/j.cnki.rao.2017.0270]
　NING Ling.Correlation between morphological changes in the macula and visual acuity before and after idiopathic macular epiretinal surgery[J].Recent Advances in Ophthalmology,2017,37(7):1068.[doi:10.13389/j.cnki.rao.2017.0270]
[6]杨天静,蒋沁,沈轶.玻璃体切割联合黄斑前膜及内界膜剥除术后患者黄斑中心凹视网膜厚度、无血管区面积及微血管密度的变化[J].眼科新进展,2021,41(4):350.[doi:10.13389/j.cnki.rao.2021.0073]
　YANG Tianjing,JIANG Qin,SHEN Yi.Changes in macular thickness, foveal avascular zone area, and vessel density after vitrectomy with epiretinal membrane and internal limiting membrane[J].Recent Advances in Ophthalmology,2021,41(7):350.[doi:10.13389/j.cnki.rao.2021.0073]

备注/Memo

备注/Memo:
河南省医学科技攻关计划省部共建备选项目（编号：2018010003）
更新日期/Last Update: 2022-07-05